Indegene and Microsoft Partner to Boost AI Innovation in Life Sciences

On July 11, 2024, Indegene announced via a stock exchange filing that it has partnered with Microsoft to advance GenAI services for global life sciences companies. They plan to develop specialised tools for medical and technology sectors to enhance AI services across commercial, medical, regulatory, and clinical functions.

Tarun Mathur, CTO of Indegene, said, “GenAI presents a once-in-a-decade opportunity for life sciences companies to modernise business processes and reimagine the effectiveness and efficiency of their operations throughout the value chain. Using GenAI, we’re working closely with many of our clients to solve specific business problems, with nearly 50 real-world use cases already in an advanced pilot stage.”

He further added, “As we double down on efforts to strengthen our innovation prowess, we will keep exploring opportunities for greater collaboration with key technology providers. We remain focused on helping our clients harness GenAI’s potential with targeted solutions to address some of their most pressing operational challenges and make their businesses future-ready.”

The strategic collaboration between Indegene and Microsoft will initially focus on several key areas:

• Content Super App: Using Azure OpenAI Service, this app streamlines content creation and tagging for life sciences companies. It offers a complete view of the content process, speeding up production, personalising content, and adopting new communication formats. It also enhances creative and video work, effectively engaging healthcare professionals, patients, and payers.
• Future-Ready Medical Content Value Chain: Generative AI is transforming medical content creation, from sourcing literature to writing core documents like Clinical Study Reports and Protocols. Indegene’s solutions speed up writing processes and ensure compliance in clinical and regulatory areas.
• Data Management and Analytics for Clinical Trials: Using Microsoft Fabric, Indegene improves data processing, reporting, and governance for clinical trials. This results in better analytics, compliance, and business agility, giving sales teams a competitive edge.

About Indegene

Indegene Limited is a digital-focused company in the life sciences sector. It supports biopharmaceutical, emerging biotech, and medical device firms in developing, launching, and growing products efficiently. Indegene blends healthcare expertise, purpose-built technology, and agile operations to offer various solutions.

On July 11, 2024, Indegene Ltd’s share price opened at ₹574.50, touching the day’s high at ₹597.70 as of 01:56 PM on the NSE.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.